Pharma & HealthcareTop Companies
Pharma & Healthcare

Top Cholesterol Meter Market Companies - Rankings, Profiles, Market Share, SWOT & Strategic Outlook

Industry

Pharma & Healthcare

Published

Feb 2026

Share:

Pharma & Healthcare

Top Cholesterol Meter Market Companies - Rankings, Profiles, Market Share, SWOT & Strategic Outlook

$3,590

Choose License Type

Only one user can use this report

Additional users can access this report

You can share within your company

Company Contents

Quick Facts & Snapshot

2025 Market Size (US$)
0.82 Billion
2026 Forecast (US$)
0.88 Billion
2032 Forecast (US$)
1.37 Billion
CAGR (2025-2032)
7.60%

Summary

The Cholesterol Meter market is in a robust growth phase, driven by preventive cardiology, home diagnostics, and decentralized primary care. Leading Cholesterol Meter market companies consolidate share through connected meters, consumables, and telehealth integrations. The market is projected to reach US$ 1.37 Billion by 2032, growing at a 7.60% CAGR from 2025.

2025 Revenue of Top Cholesterol Meter Suppliers
ReportMines Logo

Source: Secondary Information and ReportMines Research Team - 2026

Ranking Methodology

Rankings of Cholesterol Meter market companies reflect a composite score blending quantitative and qualitative indicators. Core metrics include 2025 Cholesterol Meter revenue, multi-year growth, recurring consumables share, and regional revenue diversity. We also evaluate installed base, volume of meters placed in primary care and home settings, and contract wins with health systems and retail pharmacy chains. Technology differentiation covers biosensor accuracy, test menu breadth, connectivity features, and regulatory approvals. Service coverage assesses distribution depth, training, and after-sales support. Each company receives normalized scores across these pillars, weighted by impact on sustainable competitive advantage and long-term value creation. The final ranking represents a balanced, data-driven view rather than a purely revenue-based league table.

Top 10 Companies in Cholesterol Meter

1
Abbott Laboratories
Cholestech LDX, Afinion Lipid Panel
North America, Europe, Asia Pacific
115,000
Abbott Park, USA
Point-of-care diagnostics, home testing, cardiovascular monitoring
Expanded cloud connectivity, bundled cardiometabolic panels with primary-care networks, selective M&A in digital diagnostics
US$ 0.18 Billion
2
Roche Diagnostics
Accutrend Plus, Cobas POCT Lipid Tests
Europe, North America, Latin America
103,000
Basel, Switzerland
In-vitro diagnostics, point-of-care, chronic disease management
Launched enhanced POCT workflow tools, expanded distributor partnerships in emerging markets, invested in connectivity middleware
US$ 0.15 Billion
3
Siemens Healthineers
CLINITEK Status Lipid, epoc Blood Analysis Platform
North America, Europe, Middle East
71,000
Erlangen, Germany
Lab diagnostics, point-of-care testing, imaging solutions
Integrated lipid testing with cardiology ecosystems, strengthened service contracts with hospital networks, optimized cartridge supply chain
US$ 0.09 Billion
4
PTS Diagnostics
CardioChek, A1CNow+ Lipid Panels
North America, Europe, Asia Pacific
450
Indianapolis, USA
Cardiometabolic point-of-care, pharmacy-based screening
Expanded retail pharmacy programs, introduced subscription consumables, targeted value-focused tenders in emerging markets
US$ 0.06 Billion
5
Alere / QuidelOrtho (legacy Alere portfolio)
LipidPro, Cholestech legacy systems
North America, Asia, Latin America
7,000
San Diego, USA
Point-of-care diagnostics, cardiometabolic testing
Portfolio rationalization, digital upgrades for legacy meters, channel consolidation to improve margins
US$ 0.05 Billion
6
Nova Biomedical
StatStrip Lipid, Nova Max Plus
North America, Europe, Middle East
1,400
Waltham, USA
Critical-care analyzers, rapid diagnostics
Integrated lipid meters into critical-care fleets, strengthened OEM partnerships, expanded hospital-based POCT programs
US$ 0.04 Billion
7
EKF Diagnostics
DiaSpect Lipid, Biosen C-Line
Europe, Africa, Asia Pacific
450
Cardiff, United Kingdom
Point-of-care analyzers, diabetes and lipid testing
Broadened OEM manufacturing base, focused on tenders in public health programs, enhanced remote calibration services
US$ 0.03 Billion
8
SD BIOSENSOR
MultiCare Lipid Meter, Standard Lipid Panel
Asia Pacific, Latin America, Middle East
2,500
Suwon, South Korea
Rapid tests, POCT devices, home diagnostics
Scaled low-cost meters for screening camps, localized manufacturing, collaborated with insurers for wellness programs
US$ 0.03 Billion
9
AccuTrend HealthTech
AccuTrend SmartLipid, AccuTrend Mobile
Asia Pacific, Middle East
210
Singapore
Connected home lipid monitoring, telehealth integrations
Partnered with digital therapeutics providers, launched app-based adherence analytics, expanded into corporate wellness
US$ 0.02 Billion
10
DiaMedica Instruments
LipiCheck Pro, CareClinic Lipid Meter
Europe, North Africa
160
Milan, Italy
Primary-care POCT, community screening devices
Focused on public tenders, improved user training platforms, introduced eco-friendly test strip packaging
US$ 0.02 Billion

Source: Secondary Information and ReportMines Research Team - 2026

Detailed Company Profiles

1

Abbott Laboratories

Abbott Laboratories is a diversified healthcare leader with a dominant position in point-of-care and home-based cardiometabolic testing.

Key Financials: 2025 Cholesterol Meter revenue US$ 0.18 Billion; segment growth 8.20% CAGR driven by POCT and home screening.
Flagship Products: Cholestech LDX, Afinion Lipid Panel, i-STAT Lipid Tests
2025-2026 Actions: Expanded connected POCT footprint, deepened partnerships with retail pharmacies, and enhanced integration with electronic health records.
Three-line SWOT: Strong POCT brand recognition and global distribution; Exposure to reimbursement pressure in mature markets; Opportunity—scaling home lipid monitoring subscriptions.
Notable Customers: CVS Health, Kaiser Permanente, NHS primary-care networks
2

Roche Diagnostics

Roche Diagnostics leverages its broad IVD ecosystem to deliver integrated lipid testing solutions across laboratory and point-of-care environments globally.

Key Financials: 2025 Cholesterol Meter revenue US$ 0.15 Billion; operating margin 17.40% supported by premium POCT positioning.
Flagship Products: Accutrend Plus, Cobas POCT Lipid Tests, CoaguChek / lipid workflow tools
2025-2026 Actions: Enhanced POCT connectivity, rolled out workflow automation, and expanded into community-based cardiovascular screening programs.
Three-line SWOT: Comprehensive diagnostics ecosystem; Less exposure in low-cost mass screening programs; Opportunity—hybrid lab-POCT models in emerging markets.
Notable Customers: University hospital systems, German sickness funds, Brazilian private labs
3

Siemens Healthineers

Siemens Healthineers integrates Cholesterol Meter solutions into hospital-centric diagnostics and cardiology ecosystems, emphasizing connectivity and service density.

Key Financials: 2025 Cholesterol Meter revenue US$ 0.09 Billion; R&D spend 9.80% of diagnostics revenue to support platform innovation.
Flagship Products: CLINITEK Status Lipid, epoc Blood Analysis Platform, Atellica POCT integrations
2025-2026 Actions: Bundled lipid testing with enterprise contracts, strengthened remote service capabilities, and expanded presence in cardiovascular centers.
Three-line SWOT: Strong hospital relationships and service contracts; Limited presence in direct-to-consumer home testing; Opportunity—cardiology-focused integrated diagnostic pathways.
Notable Customers: Cleveland Clinic, NHS Trust hospitals, Middle East tertiary-care networks
4

PTS Diagnostics

PTS Diagnostics focuses on cardiometabolic point-of-care testing, particularly within pharmacies, physician offices, and community screening programs.

Key Financials: 2025 Cholesterol Meter revenue US$ 0.06 Billion; recurring consumables share exceeds 70.00% of segment sales.
Flagship Products: CardioChek, CardioChek Plus, A1CNow+ Lipid Panels
2025-2026 Actions: Scaled pharmacy-based screening initiatives, introduced flexible subscription pricing, and optimized channel partnerships in cost-sensitive markets.
Three-line SWOT: Strong value proposition for pharmacies; Smaller global footprint than diversified giants; Opportunity—leveraging corporate wellness and insurer partnerships.
Notable Customers: Walgreens, regional physician office networks, employer wellness providers
5

Alere / QuidelOrtho (legacy Alere portfolio)

QuidelOrtho manages a legacy Alere Cholesterol Meter portfolio, leveraging a broad POCT footprint and installed base across clinics and labs.

Key Financials: 2025 Cholesterol Meter revenue US$ 0.05 Billion; margin uplift 1.80 percentage points through portfolio rationalization.
Flagship Products: LipidPro, legacy Cholestech analyzers, Ortho POCT lipid tests
2025-2026 Actions: Modernized connectivity on legacy meters, rationalized SKUs, and focused on higher-margin segments and strategic geographies.
Three-line SWOT: Large installed base and recognized brands; Aging platforms in some markets; Opportunity—upgrading users to next-generation connected meters.
Notable Customers: Independent clinical labs, community clinics, Latin American health ministries
6

Nova Biomedical

Nova Biomedical supplies critical-care analyzers and rapid tests, integrating lipid measurements into multi-parameter point-of-care systems.

Key Financials: 2025 Cholesterol Meter revenue US$ 0.04 Billion; POCT revenue share 32.00% of company turnover and rising.
Flagship Products: StatStrip Lipid, Nova Max Plus, Nova CRT POCT platforms
2025-2026 Actions: Expanded multi-analyte analyzers, strengthened OEM partnerships, and deepened penetration in hospital-based POCT settings.
Three-line SWOT: Strong in critical care and multi-analyte testing; Less brand awareness in retail channels; Opportunity—multi-marker cardiometabolic panels.
Notable Customers: Large US hospital systems, Middle Eastern health authorities, OEM partners
7

EKF Diagnostics

EKF Diagnostics delivers point-of-care instruments and reagents, emphasizing affordable cardiometabolic testing for public health and emerging markets.

Key Financials: 2025 Cholesterol Meter revenue US$ 0.03 Billion; diagnostics revenue CAGR 6.50% over the last three years.
Flagship Products: DiaSpect Lipid, Biosen C-Line, Quo-Test lipid add-ons
2025-2026 Actions: Expanded OEM manufacturing, pursued national tenders, and invested in remote support to reduce field-service costs.
Three-line SWOT: Competitive pricing and OEM capabilities; Limited direct brand strength in North America; Opportunity—expanding African and Asian public-health programs.
Notable Customers: National health ministries, European GP practices, OEM instrument partners
8

SD BIOSENSOR

SD BIOSENSOR is a fast-growing diagnostics manufacturer focused on rapid tests and affordable point-of-care devices, including lipid meters.

Key Financials: 2025 Cholesterol Meter revenue US$ 0.03 Billion; emerging-market revenue mix exceeds 75.00% of segment sales.
Flagship Products: MultiCare Lipid Meter, Standard Lipid Panel, Standard F POD
2025-2026 Actions: Localized production hubs, partnered with NGOs for screening campaigns, and developed low-cost, battery-efficient meters.
Three-line SWOT: Cost leadership and strong presence in Asia; Reliance on price-sensitive tenders; Opportunity—scaling via NGO and insurer wellness contracts.
Notable Customers: Indian public health programs, Southeast Asian clinics, Latin American distributors
9

AccuTrend HealthTech

AccuTrend HealthTech is a regional innovator offering app-connected home Cholesterol Meters with strong telehealth and coaching integrations.

Key Financials: 2025 Cholesterol Meter revenue US$ 0.02 Billion; digital subscription revenue already 18.00% of total.
Flagship Products: AccuTrend SmartLipid, AccuTrend Mobile, AccuTrend Cloud Coach
2025-2026 Actions: Integrated with digital therapeutics platforms, launched adherence analytics dashboards, and targeted employer wellness contracts.
Three-line SWOT: Advanced connectivity and data analytics; Limited manufacturing scale; Opportunity—white-label offerings for larger Cholesterol Meter market companies.
Notable Customers: Regional telehealth platforms, self-insured employers, private cardiology clinics
10

DiaMedica Instruments

DiaMedica Instruments serves primary care and community health centers with compact, easy-to-use Cholesterol Meters and screening devices.

Key Financials: 2025 Cholesterol Meter revenue US$ 0.02 Billion; European revenue share 68.00% with stable reimbursement support.
Flagship Products: LipiCheck Pro, CareClinic Lipid Meter, DiaMedica ScreenStation
2025-2026 Actions: Won public screening tenders, expanded multilingual training tools, and introduced sustainable packaging for test strips.
Three-line SWOT: Strong relationships with European public buyers; Limited footprint outside Europe; Opportunity—replicating public-tender model in North Africa.
Notable Customers: Italian regional health authorities, French community clinics, North African NGOs

SWOT Leaders

Abbott Laboratories

SWOT Snapshot

SWOT
Strengths

Global distribution, strong POCT portfolio, and leading home testing brands with broad cardiometabolic coverage.

Weaknesses

Premium pricing in some markets and complex organizational structure slowing smaller-market customization.

Opportunities

Rising use of home lipid monitoring, insurer-backed prevention programs, and cross-selling with glucose monitoring.

Threats

Intensifying competition from low-cost Asian vendors and ongoing reimbursement and regulatory shifts.

Roche Diagnostics

SWOT Snapshot

SWOT
Strengths

Deep IVD ecosystem, strong European presence, and robust connectivity tools linking lab and POCT workflows.

Weaknesses

Less competitive in very-low-cost tenders and constrained agility in consumer-facing channels.

Opportunities

Growth of decentralized testing, public screening campaigns, and integrated chronic-care pathways in emerging markets.

Threats

Pricing pressure from regional players and hospital budget constraints delaying instrument upgrades.

Siemens Healthineers

SWOT Snapshot

SWOT
Strengths

Strong hospital relationships, enterprise service contracts, and integrated diagnostics and imaging offerings.

Weaknesses

Limited focus on direct-to-consumer Cholesterol Meters and slower innovation in compact home devices.

Opportunities

Cardiac-center expansion, multi-marker panels, and integrated cardiovascular service bundles with long-term contracts.

Threats

Procurement-driven commoditization of POCT devices and competition from agile digital-first Cholesterol Meter market companies.

Cholesterol Meter Market Regional Competitive Landscape

North America remains the largest regional market, supported by strong payer focus on preventive cardiology and broad access to POCT in retail pharmacies and clinics. Abbott Laboratories, PTS Diagnostics, Roche Diagnostics, and Nova Biomedical lead penetration, while digital-native Cholesterol Meter market companies increasingly supply connected home meters integrated with telehealth platforms.

Europe shows balanced demand between hospital-based POCT and primary-care use, underpinned by structured cardiovascular risk management guidelines. Roche Diagnostics and Siemens Healthineers leverage long-standing hospital relationships, while DiaMedica Instruments and EKF Diagnostics win tenders in public screening programs. Regulatory emphasis on quality and data interoperability favors established Cholesterol Meter market companies with CE-marked, connected platforms.

Asia Pacific is the fastest-growing region, driven by rising dyslipidemia prevalence, large screening initiatives, and expanding private healthcare infrastructure. SD BIOSENSOR and Abbott Laboratories gain share through affordable meters and localized manufacturing. Regional governments support community screenings, opening space for value-focused Cholesterol Meter market companies and innovative, smartphone-linked devices targeting rural populations.

Latin America exhibits steady adoption of Cholesterol Meters across private labs, employer wellness programs, and government campaigns. Roche Diagnostics, SD BIOSENSOR, and Alere / QuidelOrtho compete on affordability, resilience against economic cycles, and service coverage. Currency volatility and uneven reimbursement push Cholesterol Meter market companies to design flexible pricing and pay-per-test models.

The Middle East and Africa region is emerging, with demand concentrated in Gulf Cooperation Council countries and selected African nations running noncommunicable disease initiatives. Siemens Healthineers and Abbott Laboratories leverage hospital projects, while EKF Diagnostics and SD BIOSENSOR supply cost-effective meters for large public-health screenings. Long-term framework agreements increasingly shape share among Cholesterol Meter market companies.

In emerging digital-health hubs such as India, Singapore, and parts of the Middle East, app-connected home monitoring ecosystems are forming. AccuTrend HealthTech and other agile players pilot subscription models bundling meters, strips, and coaching. Partnerships with virtual-care providers intensify competition for incumbent Cholesterol Meter market companies seeking consumer engagement capabilities.

Cholesterol Meter Market Emerging Challengers & Disruptive Start-Ups

Emerging Challengers & Disruptive Start-Ups

LipoSense Analytics
Disruptor
USA

Cloud-native lipid monitoring platform combining connected meters, AI-based risk scoring, and integration into employer wellness and payer care-management programs.

CardioCheck NanoLabs
Disruptor
Germany

Developing microfluidic cholesterol meters delivering lab-comparable accuracy from ultra-small samples, targeting primary care and home monitoring segments.

HealthVista Diagnostics
Disruptor
India

Offers low-cost Bluetooth-enabled Cholesterol Meters designed for mass screening camps, with multilingual mobile apps and offline data capture features.

LipidIQ MedTech
Disruptor
United Kingdom

Combines near-patient lipid testing with digital therapeutics, offering personalized lifestyle coaching linked directly to test results and clinician dashboards.

BioTrack Middle East
Disruptor
United Arab Emirates

Regional startup integrating Cholesterol Meters into smart clinic kiosks deployed in malls and workplaces, enabling quick screening and teleconsultation access.

CholCheck GreenLabs
Disruptor
Canada

Focuses on eco-friendly single-use cartridges and recyclable meter components, appealing to health systems with strong sustainability mandates.

Cholesterol Meter Market Future Outlook & Key Success Factors (2026-2032)

From 2025 to 2031, cumulative investments in metro expansions and station safety upgrades are projected to surpass significant amounts. The total market will scale from US$ 2.27 Billionin 2025 to US$ 3.38 Billion by 2031, reflecting a 6.90% CAGR. Winning Cholesterol Meter market companies will share several attributes. First, they will embed native IoT sensors, enabling predictive maintenance contracts that can double recurring revenue within five years. Second, modular design philosophies—interchangeable panels, plug-and-play controllers—will shorten installation windows and appeal to cost-sensitive public operators.

Localization strategies will also define competitive edges. Suppliers that establish regional assembly plants to meet content rules in India, Brazil, or the U.S. are likely to capture bonus points in tenders. Finally, sustainability credentials will move from optional to mandatory. Recyclable composite panels, energy-efficient brushless motors, and life-cycle carbon disclosures will become bid differentiators. In short, the coming decade rewards Cholesterol Metermarket companies that marry digital intelligence with manufacturing agility and regulatory foresight.

Frequently Asked Questions

Find answers to common questions about this company report.